Head-to-head · WeighScore
Fresh Day Meds vs NativeMed
By GLP-1 ScorecardUpdated
Score comparison
Fresh Day Meds has the higher recorded score — 84.3/100 to 62.7/100.
Fresh Day Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Tight both-molecule spread ($133/$166), verified and nationwide.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Fresh Day Meds | NativeMed |
|---|---|---|
| WeighScore | 84.3/100 | 62.7/100 |
| Grade | B | C |
| Site position | #18 | #301 |
| Semaglutide | $133/mo | $149/mo (promotional rate, compounded) |
| Tirzepatide | $166/mo | $183/mo (promotional rate, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #18 · B
Strengths
- $133 sema / $166 tirz
- All 50 states, LegitScript-verified
- Both molecules
What to consider
- Injection-only
- Monitoring detail not published
- Newer brand
Site position #301 · C
FDAWarning letter issued to NativeMed LLC dba NativeMed in June 2026. See the FDA warning-letter database.
Strengths
- LegitScript Certified (verifiable in the footer)
- Promotional pricing shown publicly: $149/mo semaglutide, $183/mo tirzepatide
- Online questionnaire intake, with a live visit added when state law requires it
What to consider
- Pharmacy partners aren't named — described only as 'USA-based' or 'accredited' pharmacies
- States served aren't listed publicly
- Prices are promotional — confirm whether they hold past month one or rise to the $299/$399 regular rate
- FDA issued NativeMed LLC dba NativeMed a warning letter in June 2026; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.